Atomoxetine warnings
Pro Research Analysisby 
Searched over 200M research papers for "atomoxetine warnings"
Consensus Meter
Atomoxetine Warnings: A Comprehensive Overview
FDA Boxed Warning on Suicidal Thinking
In 2005, the FDA issued a Public Health Advisory regarding the risk of suicidal thinking in children and adolescents treated with atomoxetine (Strattera). This led to the addition of a boxed warning on the drug's labeling. The warning was intended to alert healthcare providers and patients about the potential risk, although subsequent studies found no significant long-term impact on the use of atomoxetine among children and adolescents.
Suicidality and Psychiatric Effects
A comprehensive review of over a decade of research on atomoxetine's safety profile found no statistically significant association between atomoxetine and suicidality. A large register-based study and a meta-analysis of 23 placebo-controlled studies reported no completed suicides and no significant increase in suicide-related events. Additionally, symptoms of psychosis and mania were primarily observed in patients with comorbid bipolar disorder or depression.
Cardiovascular Risks
Atomoxetine has been associated with modest increases in heart rate and blood pressure. These changes are generally small and stabilize over time, returning to baseline upon discontinuation of the drug. However, patients with pre-existing cardiovascular conditions should be closely monitored, as the drug can exacerbate these issues. Long-term studies have shown that while some patients experience significant increases in blood pressure and heart rate, these effects are not typically clinically significant.
Hepatic Effects
Atomoxetine has been linked to rare cases of severe liver injury, including one case requiring liver transplantation. The drug's manufacturer has reported a few instances of reversible hepatitis and other hepatic adverse events, although these are uncommon. Patients with pre-existing liver conditions should use atomoxetine with caution.
Growth and Development
In children and adolescents, atomoxetine can cause decreases in weight and height gain, particularly in those who are above average in these metrics. However, these effects appear to be reversible over a period of 2-5 years. Monitoring growth parameters is recommended during treatment.
Other Adverse Effects
Common adverse events associated with atomoxetine include decreased appetite, nausea, dry mouth, insomnia, and erectile dysfunction. These side effects are generally mild and tend to diminish over time . Atomoxetine is not associated with QT interval prolongation, making it a safer option for patients concerned about cardiac rhythm abnormalities.
Special Populations and Off-Label Use
Atomoxetine is also being explored for off-label uses in adults, including mood disorders, eating disorders, cognitive dysfunction, and addiction treatment. However, caution is advised due to the potential for increased blood pressure and other adverse effects. Patients with narrow-angle glaucoma, epileptic seizures, Tourette's syndrome, urinary outflow obstruction, or those who are pregnant or lactating should avoid atomoxetine or use it under strict medical supervision.
Conclusion
Atomoxetine is a valuable treatment option for ADHD, offering benefits as a non-stimulant medication. While it carries some risks, particularly related to cardiovascular and hepatic health, these are generally manageable with proper monitoring. The FDA's boxed warning on suicidality has not significantly altered its use, and comprehensive reviews suggest that the drug is safe for most patients when used as directed.
Sources and full results
Most relevant research papers on this topic